Hematologic Malignancy
Mantle Cell Lymphoma
CI-CAN-00005962MCLExplore in graph →
Hematologic180 active trials5 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005962MCLExplore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (121)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07799220 | A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07684950 | Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy | not yet recruiting | Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 58 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07569965 | Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in High-Risk MCL(FRONTIER) | not yet recruiting | Phase 2 | 52 | Miltenyi Biomedicine GmbHINDUSTRY | 0 | May 6, 2026 | clinicaltrials |
| NCT07207785 | PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma(FIL_PUMA) | not yet recruiting | Phase 2 | 56 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07206264 | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment(ADAPT-MCL) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06656221 | A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 29 | Ruijin HospitalOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06427213 | This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | not yet recruiting | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 0 | May 23, 2024 | clinicaltrials |
| NCT06324994 | Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | not yet recruiting | Phase 2 | 10 | Dalian Medical UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT06255704 | A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients(Z+RCHOP/RDHAP) | not yet recruiting | Phase 2 | 23 | Shanxi Province Cancer HospitalOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04913103 | Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL(CLSGMCLPOLA) | not yet recruiting | Phase 2 | 21 | Czech Lymphoma Study GroupOTHER | 1 | Jun 4, 2021 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials